Identification of a vesicular nucleotide transporter

Keisuke Sawada* Noriko Echigo† Narinobu Juge‡
Takaaki Miyaji** Masato Otsuka†† Hiroshi Omote‡‡
Akitsugu Yamamoto§ Yoshinori Moriyama¶

*Okayama University
†Okayama University
‡Okayama University
**Okayama University
††Okayama University
‡‡Okayama University
§Nagahama Institute of Technology
¶Okayama University, moriyama@pharm.okayama-u.ac.jp

This paper is posted at eScholarship@OUDIR : Okayama University Digital Information Repository.
http://escholarship.lib.okayama-u.ac.jp/biochemistry/8
Identification of a Vesicular Nucleotide Transporter

Keisuke Sawada¹, Noriko Echigo¹, Narinobu Juge¹, Takaaki Miyaji¹, Masato Otsuka², Hiroshi Omote¹, Akitsugu Yamamoto³, and Yoshinori Moriyama¹,²

¹Department of Membrane Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, and ²Advanced Science Research Center, Okayama University, Okayama 700-8530, JAPAN, ³Department of Cell Biology, Nagahama Institute of Technology, Nagahama 526-0829, JAPAN

The first three authors contributed equally to the present study.

Correspondence and reprints should be addressed to Y. M. (e-mail: moriyama@pharm.okayama-u.ac.jp)

YM and HO designed research, analyzed data and wrote the paper. KS, NE, NJ, TM, MO performed research. AY contributed immunoelectronmicroscopy.

The authors declare no conflict of interest.

Key words: chromaffin granule, synaptic vesicle, ATP, storage and exocytosis, purinergic signaling.
ATP is a major chemical transmitter in purinergic signal transmission. Before secretion, ATP is stored in secretory vesicles found in purinergic cells. Although the presence of active transport mechanism(s) for ATP has been postulated for a long time, the protein(s) responsible for its vesicular accumulation remains unknown. The transporter encoded by the human and mouse SLC17A9 gene, a novel member of an anion transporter family, was predominantly expressed in the brain and adrenal gland. The mouse and bovine counterparts were associated with adrenal chromaffin granules. Proteoliposomes containing purified transporter actively took up ATP, ADP and GTP using membrane potential as the driving force. The uptake properties of the reconstituted transporter were similar to that of the ATP uptake by synaptic vesicles and chromaffin granules. Suppression of endogenous SLC17A9 expression in PC12 cells decreased exocytosis of ATP. These findings strongly suggest that SLC17A9 protein is a vesicular nucleotide transporter and should lead to the elucidation of the molecular mechanism of ATP secretion in purinergic signal transmission.
Vesicular storage and subsequent exocytosis of neurotransmitters is essential for chemical transmission in neurons and endocrine cells. Thus far four distinct classes of transporters are known to participate in the uptake of neurotransmitters into neuronal synaptic vesicles and secretory granules in endocrine cells. These are vesicular monoamine transporters (VMAT), vesicular acetylcholine transporters (VAcT), vesicular inhibitory amino acid transporters (VIAAT) and vesicular glutamate transporters (VGLUT) (1-7). These vesicular transporters mediate the active accumulation of the respective neurotransmitters through an electrochemical gradient of protons across the membrane generated by vacuolar proton-ATPase. ATP is stored in secretory vesicles and subsequently exocytosed, which leads to the various purinergic responses such as central control of autonomic functions, pain and mechanosensory transduction, neural-glial interactions, control of vessel tone and angiogenesis, and platelet aggregation through purinoceptors, thus establishing its role as a chemical transmitter (8-12). Since the concentration of nucleotides in the vesicles was maintained at around 0.1 to 1 M, an active transport mechanism(s) to accumulate nucleotides has been postulated (8-18). Although evidence increasingly supports the presence of a vesicular ATP transporter(s) in secretory vesicles such as synaptic vesicles and adrenal chromaffin granules (13-19), the protein(s) responsible for the ATP accumulation has not yet been identified.

Here, we report the expression and function of human and mouse SLC17A9, a novel isoform of SLC17 phosphate transporter family. We present evidence that the SLC17A9 protein acts as a vesicular nucleotide transporter and that it plays an essential role in vesicular storage of ATP in the ATP-secreting cells.

Results and discussion

Gene Organization and Expression of SLC17A9. SLC17 is a type I phosphate transporter family consisting of eight genes that are classified into three distinct subfamilies:
a) SLC17A1-4 (NPT1, NPT3, NPT4 and Na⁺/PO₄²⁻-cotransporter homologue), Na⁺ and inorganic phosphate co-transporters, b) SLC17A5 (sialin), a lysosomal H⁺/sialic acid co-transporter and c) SLC17A6-8, vesicular glutamate transporters (VGLUT) (5). We found that a fourth subfamily tentatively designated SLC17A9 was identified in a genome data bank screening (Fig. 1A). SLC17A9 was located on chromosome 20 and contained 14 exons and 13 introns (supporting information (SI) Fig. 7). The SLC17A9 protein was 430 amino acid residues long with 12 putative transmembrane helices with around 23 - 29% identity and 41 - 48% similarity to that of other SLC17 members (Fig. 1B and SI Fig. 8). Orthologues of other mammalian species have been identified. Although amino acid sequences of the amino terminal region in mammals exhibited species-specific variation, the remaining regions showed the relatively well-conserved features (83% identity) (SI Fig. 9).

We cloned cDNA encoded SLC17A9 (SI Fig. 8). Northern blot analysis indicated that the SLC17A9 and mouse counterpart (mSLC17A9) were widely expressed in various organs, but predominantly in the adrenal gland, brain and thyroid gland (Fig. 2A). In mouse adrenal gland, the mSLC17A9 protein was specifically expressed in the medulla and was associated with chromaffin granules (Fig. 2B,C). The presence of a SLC17A9 counterpart in bovine adrenal chromaffin granule membrane has been confirmed (Fig. 2D).

**SLC17A9 protein is an ATP transporter.** We hypothesized that SLC17A9 is responsible for the storage of nucleotides in chromaffin granules, in which high concentrations of ATP and other nucleotides (~0.2 M) are accumulated in a membrane potential (Δψ)-dependent manner (8, 13, 16). To test this working hypothesis, the SLC17A9 protein was expressed in High Five cells, solubilized from the membranes and purified by Ni-NTA column chromatography (Fig. 3A). The purified fraction showed two major protein bands (68 and 63kDa) on SDS polyacrylamide gel, which corresponded to SLC17A9 protein because of their immunological reactivity to anti-SLC17A9 antibodies.
and ability to bind ATP upon UV light illumination (Fig. 3A). The observation of two SLC17A9 protein bands upon polyacrylamide gel electrophoresis could have been due to conformational differences or modification.

We then reconstituted SLC17A9 protein into liposomes, and investigated whether or not the proteoliposomes took up [α-32P]ATP. When an internal inside positive Δψ was established such as a K+‐diffusion potential through the addition of valinomycin, the proteoliposomes took up [α-32P]ATP in a time‐dependent manner (Fig. 3B, C and SI Table 1). ATP uptake was not observed in liposomes that did not contain SLC17A9 protein even when Δψ was already established (Fig. 3C). In contrast, artificially imposing pH gradient (ΔpH) did not evoke the ATP uptake (SI Table I). The valinomycin‐evoked ATP uptake exhibited dose‐dependence with Km and Vmax values of 0.8 mM and 138 nmol/min/mg protein, respectively (Fig. 3C). These results demonstrated that the SLC17A9 protein was an active transporter of ATP and used Δψ (positive inside) but not ΔpH (acidic inside) as the driving force.

Characterization of Nucleotide Transport. We further characterized the ATP uptake by SLC17A9 protein. Since ATP is a trivalent anion at the physiological pH and behaves as a monovalent anion upon chelation with divalent cations such as Mg2+, we asked which forms were recognized as transport substrates. We found that Mg2+ and Ca2+ did not affect the ATP uptake (Fig. 4A), suggesting that this transporter recognized ATP as a substrate irrespective of its charge status. Cl− dependence on the ATP uptake is of interest because VGLUT, another subfamily of SLC17, absolutely requires Cl− for transport activity (20), and Cl− stimulates ATP uptake in chromaffin granule membrane vesicles (16). As expected, the presence of Cl− was an absolute requirement for ATP transport activity in the SLC17A9 protein (Fig. 4B). The transport activity reached steady state at ~4 mM Cl−, while the magnitude of Δψ was unchanged. Br− also activated ATP transport, while
sulfate was not effective (SI Fig. 10). Various anions such as iodine and thiocyanate were rather inhibitory. The anion dependence of the SLC17A9 protein was similar to that of VGLUT (21, 22), suggesting the presence of a similar anion binding site and regulatory mechanism in this transporter family. Cis-inhibition studies suggested that this transporter preferentially recognized ATP, GTP and ADP as transport substrates. AMP-PNP and γS-ATP, non-hydrolysable ATP analogues, and diadenosine triphosphate (AP3A), one of the unique physiological ATP derivatives that accumulates in chromaffin granules and synaptic vesicles (9, 18), strongly inhibited the uptake. In contrast, adenosine and adenine were less effective inhibitors (Fig. 4C). The transporter-mediated uptake of GTP and ADP was confirmed by the direct measurement of ADP and GTP uptake (Fig. 4D). The ATP uptake was greatly inhibited by 4,4′-diisothiocyanatostilbene-2, 2′-disulfonate (DIDS), an inhibitor of VGLUT (23). The concentration required for 50% inhibition (ID50) was 1.5 μM (Fig. 4E). DIDS also inhibited the uptake of GTP and ADP (Fig. 4D). Evans blue, a specific inhibitor of VGLUT (23), also potently inhibited the ATP uptake with an ID50 of 40 nM (Fig. 4F). Atractyloside, an inhibitor of the mitochondrial ATP/ADP exchanger, inhibited the ATP uptake of the SLC17A9 protein only in the presence of Mg2+ as reported for ATP uptake in chromaffin granules (16) (Fig. 4G). Thus, the SLC17A9 protein is a Cl−-dependent nucleotide transporter, whose properties are very similar, if not identical, to those observed for ATP uptake in chromaffin granules (8, 13, 15-17).

**Involvement of SLC17A9 protein in vesicular storage and exocytosis of ATP.** Finally, we investigated whether SLC17A9 is responsible for vesicular storage and subsequent exocytosis of ATP in purinergic cells. PC12 cells are known to store and secrete ATP through secretory granule-mediated exocytosis (24). We found that mSLC17A9 protein was associated with secretory granules (Fig. 5A) and that RNA interference suppressed about 53% of SLC17A9 expression and about 50% of KCl-stimulated exocytosis of ATP.
from PC12 cells, while the control treated with scrambled siRNA did not show any inhibitory effect (Fig. 5B and C). These results supported the participation of SLC17A9 protein in vesicular storage and exocytosis of ATP.

**SLC17A9 protein as a vesicular nucleotide transporter.** Based on this information, we concluded that SLC17A9 and its orthologues encode the **vesicular nucleotide transporter (VNUT).** SLC17A9 protein may accumulate ATP and other nucleotides in the secretory vesicles such as adrenal chromaffin granules and synaptic vesicles. SLC17A9 protein is a long-searched nucleotide transporter and seems to be a missing link in purinergic chemical transmission (Fig. 6). Our immunohistochemical studies with anti-mSLC17A9 antibodies indicated that mSLC17A9 protein is expressed in a population of astrocytes, suggesting involvement of this transporter in storage and subsequent exocytosis of ATP from these cells (manuscript in preparation) (25-27). Thus, identification of SLC17A9 protein as a vesicular nucleotide transporter may reveal the molecular mechanisms how ATP is secreted from purinergic cells, and provide a novel molecular target for the pathophysiology of purinergic signaling and its therapeutic potential (9-11). Phylogenetic analysis indicates that the orthologues of SLC17A9 are widely distributed among various invertebrates as well as vertebrates (SI Fig. 11). Thus, our findings suggest the occurrence of common molecular mechanisms of the purinergic chemical transmission in animals.

**Materials and Methods**

**Expression and purification of SLC17A9 protein.** Recombinant baculovirus containing human SLC17A9 cDNA were constructed using the Bac-to-Bac baculovirus expression systems (Invitrogen) according to the manufacture’s protocol. SLC17A9 cDNA was amplified by PCR using the primers (5'-
CACCATGACCCTGACAAGCAGGCGCCAGGA -3' and 5'-CTAGAGGTCTTCTGGTGTTAGGCTC -3'). Sf9 or High Five cells were used for expression of SLC17A9 protein. Insect cells were infected by recombinant baculoviruses at a multiplicity of infection (m. o. i.) of 2 and cultured a further 72 h for Sf9 cells and 48 h for High Five cells. The cell (1~2 x 10^8 cells) were suspended in a buffer containing 20 mM Tris-HCl, pH 8.0, 0.1 M potassium acetate, 10% glycerol, 0.5 mM dithiothreitol, 10 μg/ml pepstatin A and 10 μg/ml leupeptin and disrupted by sonication with a TOMY UD200 tip sonifier. Cell lysates were centrifuged at 700 x g for 10 min to remove debris and the resultant supernatant was centrifuged at 160,000 x g for 1 h. The pellet (membrane fraction) was suspended in buffer containing 20 mM MOPS-Tris, pH 7.0, 10% glycerol, 10 μg/ml pepstatin A and 10 μg/ml leupeptin at approximately 6 mg protein/ml, and was solubilized with 2% octylglucoside. After centrifugation at 260,000 x g for 30 min, the supernatant was taken and applied to 1 ml of Ni-NTA Superflow resin (Qiagen). After incubation for 4 h at 4°C, the resin was washed with 10 ml of 20 mM MOPS-Tris pH 7.0, 5 mM imidazole, 20% glycerol and 1% octylglucoside. SLC17A9 protein was eluted from the resin with 3 ml of the same buffer containing 60 mM imidazole and could be stored at -80°C without loss of activity for at least a few months.

Reconstitution. Reconstitution of purified SLC17A9 protein into liposomes was carried out by the freeze-thaw method as described (20). In brief, 10 μg SLC17A9 protein was mixed with asolectin liposomes (0.5 mg lipid), frozen at -80°C and left at this temperature for at least 5 min. The mixture was thawed quickly by holding the samples tube in the hands and diluted 60-fold with reconstitution buffer containing 20 mM MOPS-Tris, pH 7.0, 0.5 mM dithiothreitol, 0.15 M sodium acetate and 2 mM magnesium acetate. Reconstituted proteoliposomes were sedimented by centrifugation at 200,000 x g for 1 h.
at 4°C, suspended in 0.2 ml of 20 mM MOPS-Tris, pH 7.0 containing 0.15 M sodium acetate and 2 mM magnesium acetate, and used within a day of preparation. Asolectin liposomes were prepared as follows: soybean lecithin (20 mg; Sigma Type IIS) was suspended in 2 ml of 20 mM MOPS-NaOH, pH 7.0 containing 0.5 mM dithiothreitol. The mixture was sonicated in a bath-type sonicator until clear, divided into small aliquots and stored at -80°C until use.

**Nucleotides transport.** Reconstituted proteoliposomes (0.5 µg protein per assay) were suspended in 500 µl of 20 mM MOPS-Tris, pH 7.0, 5 mM magnesium acetate, 4 mM KCl and 0.15 M potassium acetate and incubated for 3 min at 27°C. Valinomycin was added to give a final concentration of 2 µM and the mixture incubated for a further 3 min. The assay was initiated by addition of 0.1 mM $[^{32}\text{P}]$ ATP (3.7 GBq/mmol) and 130 µl aliquots were taken at the times indicated and centrifuged through a Sephadex G-50 (fine) spin column at 760 x g for 2 min (20). Radioactivity and protein concentration of the eluate were measured. In the case of GTP or ADP transport, $[^{32}\text{P}]$ GTP (3.7 GBq/mmol) or [2, 8-$^3$H] ADP (0.37 GBq/mmol) were used for the substrates instead of ATP.

**Cell culture and RNA interference (RNAi)**

PC12 cells were cultured as described (24). HiPerFect transfection reagent (Qiagen) was used for transfection of 25 nM AllStars negative control siRNA or rat SLC17A9 siRNA: UAUUCGAGAGAAUGUCACG. KCl-stimulated ATP secretion was assayed as described 3 days later (24).

**Data analysis.** All numerical values are shown as the mean ± SEM. n = 3-6. Statistical significance was determined by the Student’s t-test. * <0.1, ** < 0.01, *** < 0.001.
Northern blot analysis, cDNA cloning, immunohistochemistry and other detailed methods are provided in SI Supplementary materials and methods.

**ACKNOWLEDGEMENTS.** NE was supported by a Research Fellowship from the Japan Society for the Promotion of Science for Young Scientists. This work was supported in part by a Grant-in-Aid from the Japanese Ministry of Education, Science, Sport, and Culture to YM.
References


**Figure Legends**

**Figure 1.** Phylogenetic tree of SLC17 family (A) and putative secondary structure of SLC17A9 protein (B).

**Figure 2.** Expression of SLC17A9 and its association with chromaffin granules. (A) Northern blotting showing expression of SLC17A9 in human and mouse brain and adrenal gland. Expression of G3PDH is also shown as a control. (B) Immunohistochemical localization of SLC17A9 protein in mouse adrenal gland. Inset shows control staining with preabsorbed antibodies. C, cortex; M, medulla. Bar = 10 μm. (C) Immunoelectronmicroscopy showing that SLC17A9 proteins (gold particles) are associated with chromaffin granules. The inset shows background labeling with control serum. Mit, mitochondrial. Bar = 100 nm. (D) Western blot indicates the presence of a SLC17A9 counterpart in the membrane of bovine adrenal chromaffin granule with a relative mobility of 61 kDa. The preabsorbed antibodies did not bind to the protein. The positions of marker proteins are indicated on the left.

**Figure 3.** Purification and reconstitution of SLC17A9 protein. (A) Purification. (left) Purified fraction (7 μg protein) was analyzed in an 11% polyacrylamide gel electrophoresis in the presence of SDS and visualized by Coomassie Brilliant Blue staining. (center) A duplicate gel was analyzed by Western blotting with anti-SLC17A9 antibodies. (right) Labeling of SLC17A9 protein upon UV light illumination with [α-32P]ATP. (B) Formation of Δψ (positive inside) was measured by oxonol-V fluorescence quenching. Proteoliposomes (0.5 μg protein) or liposomes (20 μg lipid) containing trapped Na⁺ was suspended in buffer containing 0.15 M K-acetate plus 4 mM KCl and 1 mM oxonol-V and fluorescence quenching was measured. Final concentration of valinomycin and CCCP
were added at 1 μM. (C) Time course of [α-32P]ATP uptake. Na+-trapped proteoliposomes or liposomes were suspended as above in the presence or absence of valinomycin. Upon the addition of [α-32P]ATP, samples were taken at the indicated times and radioactivity taken up by the proteoliposomes was counted. Inset. Dose dependence of ATP uptake.

**Figure 4.** Characterization of nucleotides transport by SLC17A9 protein. (A) The effect of divalent cations on the [α-32P]ATP uptake in the absence or presence of 2 mM Mg2+ or Ca2+ or 0.5 mM EGTA. (B) Dependence of [α-32P]ATP uptake on [Cl-]. The uptake was measured after 2 min. Part of the potassium acetate in the reaction mixture was replaced with the indicated concentration of KCl. The magnitude of Δψ (oxonol V-fluorescence quenching) was little affected under the assay conditions employed. (C) [α-32P]ATP uptake in the presence of various nucleotides at 1 mM. (D) Uptake of radiolabeled GTP or ADP transport in the presence or absence of valinomycin. When indicated, DIDS at 2 μM was included. (E-G) The effect of DIDS, Evans blue and atractyloside on [α-32P]ATP uptake in the presence or absence of Mg-acetate. Atractyloside was included at 200 μM.

**Figure 5.** The impact of rat SLC17A9 siRNA on the endogenous expression of SLC17A9 in PC12 cells was compared to cells treated with scrambled siRNA (control). (A) Double labeling immunohistochemistry indicated that SLC17A9 protein was co-localized at least in part with synaptotagmin, a marker of secretory granule, but not with synaptophysin, a marker of synaptic-like microvesicles in cultured PC12 cells. (B, C) Both SLC17A9 mRNA levels (B), as determined by real-time PCR, and the KCl-dependent secretion of ATP after 30 min (C) were assessed. n= 9, 3 independent experiments.

**Figure 6.** Schematic presentation of purinergic chemical transmission. VNUT is present in secretory vesicles and is responsible for vesicular storage of nucleotides. The accumulated
nucleotides, in particular ATP, are exocytosed upon stimulation, bind to purinoceptors at the surface of target cells which then triggers intracellular signal transmission.
Figure 1
Figure 2

A

<table>
<thead>
<tr>
<th>Species</th>
<th>Organ</th>
<th>SLC17A9</th>
<th>G3PDH</th>
</tr>
</thead>
<tbody>
<tr>
<td>Human</td>
<td>Testis</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Adrenal</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Bladder</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Throat</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Heart</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Skeletal muscle</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Kidney</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Liver</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>Lung</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Species</th>
<th>Organ</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mouse</td>
<td>Testis</td>
</tr>
<tr>
<td></td>
<td>Adrenal</td>
</tr>
<tr>
<td></td>
<td>Bladder</td>
</tr>
<tr>
<td></td>
<td>Throat</td>
</tr>
<tr>
<td></td>
<td>Heart</td>
</tr>
<tr>
<td></td>
<td>Skeletal muscle</td>
</tr>
<tr>
<td></td>
<td>Kidney</td>
</tr>
<tr>
<td></td>
<td>Liver</td>
</tr>
<tr>
<td></td>
<td>Lung</td>
</tr>
</tbody>
</table>

B

C

D

KDa

115-

72-

57-

39-

34-
Figure 3

A

CBB staining Western blotting [\(\alpha^{32}\text{-P}]\text{ATP}\) labeling

B

Proteoliposomes Ethanol CCCP Val Liposomes

C

ATP uptake (nmol/mg protein)

ATP uptake (nmol/mg protein)
Figure 4

A

ATP uptake (nmol / mg protein)

B

ATP uptake (nmol/mg) (% ATP)

C

ATP uptake (nmol / mg protein)

D

Nucleotide uptake (nmol / mg protein)

E

ATP uptake (%)

F

Evans blue uptake (%)

G

Atractyloside uptake (%)

Legend:
- Val
- Mg
- Ca
- EGTA
- GTP
- ADP
- AMP
- Adenine
- ATP
- AMP-PNP
- ATPγP
- AP5A
- Pyrophosphate
- Chloride (mM)
- Conc. (µM)

Notes:
- Varies in bar graphs and line graphs.

Significance levels:
- * p < 0.05
- ** p < 0.01
- *** p < 0.001
- **** p < 0.0001

Time (min)

Conc. (µM)
Figure 5
Figure 6
Supplementary information

Supplementary materials and methods

cDNAs. cDNA of SLC17A9 was cloned by PCR from Mammalian Gene Collection clone 4563089. For the construction of cDNA, we used pENTR Directional TOPO cloning Kits (Invitrogen). The primers used were based on database sequences (Genbank No. CAC28600): sense primer, CACCATGACCCCTGACAAGCAGGCGCCAGGA; antisense primer, CTAGAGGTCTCTCATGGGTAGAGCTC. The sequence was confirmed by comparison with the human genome sequence and any differences corrected. cDNAs of mouse SLC17A9 was cloned as described above. cDNA of mouse SLC17A9 was amplified by RT-PCR using RNA derived from mouse adrenal gland. The following primers were used; sense primer, 5’- CACCATGCCATCCCAGCGCTCTA-3’, antisense primer, 5’-TTCACTGACAGGGTTGTTATCC-3’.

Northern blot analysis. Human and mouse multiple-tissue Northern blots (MTN) were purchased from Clontech. For Northern blot analysis, PCR fragments encoding the N-terminal 425 bps (223-647) of human SLC17A9 and C-terminal 758 bps (891 – 1648) of mouse SLC17A9 labeled with 32P-dCTP were used as probes. Hybridization was performed at 68 °C for 1 h in Express Hyb hybridization solution (Clontech) and washed under high-stringency conditions at 50 °C.

Antibodies. Site-specific polyclonal antibodies against human and mouse SLC17A9 were prepared by repeatedly injecting GST-fusion polypeptides encoding either M1-I40 or L8-R97, respectively. The antiserum (100 µl) was preabsorbed by incubating it with the antigen (1 mg) at 4 °C overnight. Monoclonal antibodies against synaptotagmin were kindly supplied by Dr. M. Takahashi (28). Anti-His-tag monoclonal antibody was from
Novagen. Alexa Fluor 488-labeled goat anti-rabbit IgG was obtained from Invitrogen (Molecular Probes) and colloidal gold conjugated goat anti-rabbit IgG from British Biocell International.

**Nucleotide binding.** Binding of nucleotides to the purified transporter was assayed by UV light illumination according to the published procedures (29). In brief, the reaction was performed in 50 µl reaction mixture containing 20 mM MOPS-Tris, pH 7.0, 50 mM potassium acetate, 2 mM magnesium acetate, 4 mM KCl, 7 µg protein and 5 µM concentration of [α-32P] ATP (15 TBq/mmol). The reaction mixture was placed in flat bottom plastic test tubes, on ice, and at a 5-cm distance from an unfiltered UV lamp (UVP Inc., 15W). After a 10 min illumination, the reaction was terminated by the addition of 10 µl of concentrated dissociation buffer to give final concentration of 2% SDS and β-mercaptoethanol. Samples (50 µl) were electrophoeresed in the presence of SDS and were exposed to an IP image plate.

**Immunohistochemistry**
Indirect immunofluorescence microscopy was performed as previously described (30). Adrenal glands were obtained from adult C57BL/6 mice perfused intracardially with 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. The first antibody treatment was performed with 1:500 diluted antibodies in phosphate-buffered saline (PBS) containing 0.5% bovine serum albumin (BSA) for 1 h at room temperature. The specimens were observed under an Olympus FV300 confocal laser microscope.

**Immunoelectronmicroscopy**
The LR White embedding immunogold method used (31). Adult C57BL/6 mice were anesthetized with ether and then perfused intracardially with saline, followed by 0.1%
glutaraldehyde and 4% paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. Adrenal gland was washed with PBS, dehydrated in ethanol series, and then embedded in LR White. Ultrathin sections (80 nm) on nickel grids were incubated with PBS containing 2% goat serum and 2% BSA for 10min, and then treated with either rabbit antiserum against mouse SLC17A9 diluted 1:20 or normal rabbit serum diluted 1:20 for 1hr at room temperature. The sections were washed and treated with secondary antibodies conjugated with 10nm colloidal gold diluted 1:50. After washing with sodium cacodylate buffer (pH 7.4), the sections were postfixed in 2.5% glutaraldehyde in the cacodylate buffer, stained sequentially uranyl acetate for 10 min and lead citrate for 1 min. Specimens were observed under a Hitachi H-7100S electron microscope.

**Measurement of Δψ and ΔpH by fluorescence quenching.**
Δψ (positive inside) was assayed by measuring the fluorescence quenching of oxonol V as described previously (20).

**Preparation of chromaffin granule membrane vesicles from bovine adrenal glands**
Chromaffin granules were isolated from bovine adrenal glands by differential centrifugation and successive sucrose density gradient centrifugation as described previously (32). After isolation, the granules were immediately disrupted under low osmotic conditions, and the resulting membrane vesicles suspension was stocked at -80 °C.

**Other procedures.** Polyacrylamide gel electrophoresis in the presence of SDS and Western blotting were performed as described (20). Protein concentration was assayed using bovine serum albumin as a standard (33).
Supplementary Figures

Figure 7. Chromosomal localization and gene organization of SLC17A9. The exon and intron organization of SLC17A9 is also shown. The open and shaded boxes show noncoded and coded exons, respectively.

Figure 8. Amino acid sequences comparison of members of SLC17 family. Identical residues are indicated by asterisks. Predicted transmembrane regions are shaded.

Figure 9. The amino acid sequences of SLC17A9 orthologues are aligned. Identical residues are indicated by asterisks. Predicted transmembrane regions are shaded. The positions of polypeptide used for preparation of antibody were boxed in red.

Figure 10. The effect of various anions on $\Delta \psi$-mediated uptake of [$\alpha$-$^{32}$P] ATP by SLC17A9 protein. A. The uptake was performed under the standard assay conditions except that KCl was replaced with various potassium salts as indicated. B. The effects of anion species on Cl–-dependent [$\alpha$-$^{32}$P]ATP uptake at 2 min in the presence of 4 mM KCl plus the indicated potassium salts (4 mM) was measured.

Figure 11. VNUT orthologues are widely distributed in the animal kingdom. A phylogenetic tree of selected genes encoding VNUT-type transporters from the animal kingdom is shown. VNUT from mammals are shown in beige, birds in coral, amphibians in dark pink, fish in blue and insects in green.
Supplementary References


<table>
<thead>
<tr>
<th>SLC17A9_VNUT</th>
<th>--------------------</th>
<th><strong>MTLTSRQQDQSQAPCEPCATM</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>SLC17A7_VGUT2</td>
<td><strong>LRSRQILTTTAVRKIMNCGGFGMEATLLLVVGFSHTKGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYSILMGSISNG</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A6_VGUT2</td>
<td><strong>LRSKQILSTTTVRKIMNCGGFGMEATLLLVVGYSHTRGVAISFLVLAVGFSGFAISGFNVNHLDIAPRYSILMGSISNG</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A5_Sialin</td>
<td><strong>--SSQK-SVPWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLPTYMKEILRFNVQENGFLSSLPYLGSWLCMILSGQAADN</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A3_NPT4</td>
<td><strong>--GSSKQPLPIKAMLRSLPIWSICLGCFSHQWLVSTMVVYIPTYISSVYHVNIRDNGLLSALPFIVAWVIGMVGGLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A2_NPT3</td>
<td><strong>--SSPGRAVPIKAMVTCLPLWAIFLGFFSHFWLCTIILTYLPTYISTLLHVNIRDSGVLSSLPFIAAASCTILGGQLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A1_NPT1</td>
<td><strong>FLTRNILSVIAVRKLFTAAGFLLPAIFGVCLPYLSSTFYSIVIFLILAGATGSFCLIGVFINGLDIAPRYSFLMGISRG</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A8_VGUT3</td>
<td><strong>VSLSKFSTPWKRFFTSLPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGEISKVGLLSAVPHLVMTIVVIPGGQIADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A6_VGUT2</td>
<td><strong>LGAMEKFKTPWRKFFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGEISKVGLLSAVPHLVMTIVVIPGGQIADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A5_Sialin</td>
<td><strong>KLLSISYAGAQLGTVISLPLSGIICYYMNWTYVFYFFGTIGIFWFLLWIWLVSDTPQKHKRISHYEKEYILSSLRNQL--</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A3_NPT4</td>
<td><strong>RLCSIALSGMLLGCFTAILIGGFISETLGWPFVFYIFGGVGCVCCLLWFVVIYDDPVSYPWISTSEKEYISSLQ</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A1_NPT1</td>
<td><strong>ILTMAPSGYLAGRVGTKRVVGISLFATSFLTLCIPLATDFG---IVLLIVTRIVQGLSQSSILGGQFAIWEKWGPPQERS</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A8_VGUT3</td>
<td><strong>IMTQIPGGFISNKFAANRVFGAAIFLTSTLNMFIPSAARVH---YGCVMCVRILQVEGTYYVACHNGMSK</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A7_VGUT1</td>
<td><strong>IVTQIPGGYASIKQMKMLIPFILGVITLTFTPILTAADGDGQPSREAMYFQGLLSSAPICGILQSSAPICGILQ</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A6_VGUT2</td>
<td><strong>RLATTSFCGSYAGAVVAMPLAGVLVQYSGWSSVFYFGSGIFWYLFWLLVSYESPAKHPTITDEERRYIEESIGESANL</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A5_Sialin</td>
<td><strong>--SSQK-SVPWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLPTYMKEILRFNVQENGFLSSLPYLGSWLCMILSGQAADN</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A3_NPT4</td>
<td><strong>---GSSKQPLPIKAMLRSLPIWSICLGCFSHQWLVSTMVVYIPTYISSVYHVNIRDNGLLSALPFIVAWVIGMVGGLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A2_NPT3</td>
<td><strong>--SSPGRAVPIKAMVTCLPLWAIFLGFFSHFWLCTIILTYLPTYISTLLHVNIRDSGVLSSLPFIAAASCTILGGQLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A1_NPT1</td>
<td><strong>IIIQVPVGYFSGIYSTKKMIGFALCLSSVLSLLIPPAAGIG---VAWVVVFQVAVQQAQ1VAQ1APFQVYVTAKQVEAG</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A8_VGUT3</td>
<td><strong>VSLSKFSTPWKRFFTSLPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGEISKVGLLSAVPHLVMTIVVIPGGQIADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A7_VGUT1</td>
<td><strong>--SSQK-SVPWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLPTYMKEILRFNVQENGFLSSLPYLGSWLCMILSGQAADN</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A6_VGUT2</td>
<td><strong>LGAMEKFKTPWRKFFTSMPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGEISKVGLLSAVPHLVMTIVVIPGGQIADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A5_Sialin</td>
<td><strong>KLLSISYAGAQLGTVISLPLSGIICYYMNWTYVFYFFGTIGIFWFLLWIWLVSDTPQKHKRISHYEKEYILSSLRNQL--</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A3_NPT4</td>
<td><strong>RLCSIALSGMLLGCFTAILIGGFISETLGWPFVFYIFGGVGCVCCLLWFVVIYDDPVSYPWISTSEKEYISSLQ</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A1_NPT1</td>
<td><strong>ILTMAPSGYLAGRVGTKRVVGISLFATSFLTLCIPLATDFG---IVLLIVTRIVQGLSQSSILGGQFAIWEKWGPPQERS</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A8_VGUT3</td>
<td><strong>VSLSKFSTPWKRFFTSLPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGEISKVGLLSAVPHLVMTIVVIPGGQIADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A7_VGUT1</td>
<td><strong>IVTQIPGGYASIKQMKMLIPFILGVITLTFTPILTAADGDGQPSREAMYFQGLLSSAPICGILQSSAPICGILQ</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A6_VGUT2</td>
<td><strong>RLATTSFCGSYAGAVVAMPLAGVLVQYSGWSSVFYFGSGIFWYLFWLLVSYESPAKHPTITDEERRYIEESIGESANL</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A5_Sialin</td>
<td><strong>--SSQK-SVPWVPILKSLPLWAIVVAHFSYNWTFYTLLTLLPTYMKEILRFNVQENGFLSSLPYLGSWLCMILSGQAADN</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A3_NPT4</td>
<td><strong>---GSSKQPLPIKAMLRSLPIWSICLGCFSHQWLVSTMVVYIPTYISSVYHVNIRDNGLLSALPFIVAWVIGMVGGLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A2_NPT3</td>
<td><strong>--SSPGRAVPIKAMVTCLPLWAIFLGFFSHFWLCTIILTYLPTYISTLLHVNIRDSGVLSSLPFIAAASCTILGGQLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A1_NPT1</td>
<td><strong>IIIQVPVGYFSGIYSTKKMIGFALCLSSVLSLLIPPAAGIG---VAWVVVFQVAVQQAQ1VAQ1APFQVYVTAKQVEAG</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A8_VGUT3</td>
<td><strong>VSLSKFSTPWKRFFTSLPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGEISKVGLLSAVPHLVMTIVVIPGGQIADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A7_VGUT1</td>
<td><strong>IVTQIPGGYASIKQMKMLIPFILGVITLTFTPILTAADGDGQPSREAMYFQGLLSSAPICGILQSSAPICGILQ</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A6_VGUT2</td>
<td><strong>RLATTSFCGSYAGAVVAMPLAGVLVQYSGWSSVFYFGSGIFWYLFWLLVSYESPAKHPTITDEERRYIEESIGESANL</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A5_Sialin</td>
<td><strong>KLLSISYAGAQLGTVISLPLSGIICYYMNWTYVFYFFGTIGIFWFLLWIWLVSDTPQKHKRISHYEKEYILSSLRNQL--</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A3_NPT4</td>
<td><strong>---GSSKQPLPIKAMLRSLPIWSICLGCFSHQWLVSTMVVYIPTYISSVYHVNIRDNGLLSALPFIVAWVIGMVGGLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A2_NPT3</td>
<td><strong>--SSPGRAVPIKAMVTCLPLWAIFLGFFSHFWLCTIILTYLPTYISTLLHVNIRDSGVLSSLPFIAAASCTILGGQLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A1_NPT1</td>
<td><strong>IIIQVPVGYFSGIYSTKKMIGFALCLSSVLSLLIPPAAGIG---VAWVVVFQVAVQQAQ1VAQ1APFQVYVTAKQVEAG</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A8_VGUT3</td>
<td><strong>VSLSKFSTPWKRFFTSLPVYAIIVANFCRSWTFYLLLISQPAYFEEVFGEISKVGLLSAVPHLVMTIVVIPGGQIADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A7_VGUT1</td>
<td><strong>IVTQIPGGYASIKQMKMLIPFILGVITLTFTPILTAADGDGQPSREAMYFQGLLSSAPICGILQSSAPICGILQ</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A6_VGUT2</td>
<td><strong>RLATTSFCGSYAGAVVAMPLAGVLVQYSGWSSVFYFGSGIFWYLFWLLVSYESPAKHPTITDEERRYIEESIGESANL</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A5_Sialin</td>
<td><strong>KLLSISYAGAQLGTVISLPLSGIICYYMNWTYVFYFFGTIGIFWFLLWIWLVSDTPQKHKRISHYEKEYILSSLRNQL--</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A3_NPT4</td>
<td><strong>---GSSKQPLPIKAMLRSLPIWSICLGCFSHQWLVSTMVVYIPTYISSVYHVNIRDNGLLSALPFIVAWVIGMVGGLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A2_NPT3</td>
<td><strong>--SSPGRAVPIKAMVTCLPLWAIFLGFFSHFWLCTIILTYLPTYISTLLHVNIRDSGVLSSLPFIAAASCTILGGQLADF</strong></td>
<td></td>
</tr>
<tr>
<td>SLC17A1_NPT1</td>
<td><strong>IIIQVPVGYFSGIYSTKKMIGFALCLSSVLSLLIPPAAGIG---VAWVVVFQVAVQQAQ1VAQ1APFQVYVTAKQVEAG</strong></td>
<td></td>
</tr>
</tbody>
</table>
ATP uptake (nmol/mg protein)

**A**

- Cl⁻
- +Val
- -Val
- Br⁻
- I⁻
- F⁻
- NO₃⁻
- SO₄²⁻
- SCN⁻
- none

**B**

- Cl⁻
- Br⁻
- I⁻
- F⁻
- NO₃⁻
- SO₄²⁻
- SCN⁻
- none

**Significance Levels**

- ***: P < 0.001
- **: P < 0.01
- *: P < 0.05
Table 1. Energetics of ATP transport.

<table>
<thead>
<tr>
<th>Inside</th>
<th>Outside</th>
<th>Ionophores</th>
<th>Inside pH</th>
<th>Outside pH</th>
<th>ATP uptake (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Na⁺</td>
<td>K⁺</td>
<td>none</td>
<td>7.0</td>
<td>7.0</td>
<td>3.1 ± 1.7</td>
</tr>
<tr>
<td>Na⁺</td>
<td>Na⁺</td>
<td>Val.</td>
<td>7.0</td>
<td>7.0</td>
<td>100.0</td>
</tr>
<tr>
<td>Nig.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>6.4 ± 2.1</td>
</tr>
<tr>
<td>Na⁺</td>
<td>K⁺</td>
<td>none</td>
<td>7.0</td>
<td>7.0</td>
<td>7.6 ± 6.8</td>
</tr>
<tr>
<td>Na⁺</td>
<td>Na⁺</td>
<td>Val.</td>
<td>7.0</td>
<td>7.0</td>
<td>6.5 ± 5.0</td>
</tr>
<tr>
<td>Nig.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4.5 ± 4.1</td>
</tr>
<tr>
<td>K⁺</td>
<td>K⁺</td>
<td>none</td>
<td>7.0</td>
<td>7.0</td>
<td>5.9 ± 2.3</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5.5</td>
<td>7.0</td>
<td>2.6 ± 0.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>5.5</td>
<td>7.5</td>
<td>2.4 ± 0.4</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>7.0</td>
<td>7.0</td>
<td>5.9 ± 5.1</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>2.4 ± 3.0</td>
</tr>
<tr>
<td>K⁺</td>
<td>Na⁺</td>
<td>none</td>
<td>7.0</td>
<td>7.0</td>
<td>2.5 ± 0.6</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3.3 ± 2.8</td>
</tr>
</tbody>
</table>

Na⁺-trapped proteoliposomes or K⁺-trapped proteoliposomes was prepared by dilution of purified transporter (10 μg protein, 150 μl) into the 3 ml of buffer consisting of 20 mM MOPS-tris, pH 7.0, 0.15 M Na-acetate (Na⁺-trapped proteoliposomes) or 0.15 M K-acetate (K⁺-trapped proteoliposomes), and centrifuged as described. The pellets were suspended in 200 μl of the same buffer. The proteoliposomes (0.5 μg protein) was added to the buffer containing 0.15 M K-acetate and 4 mM KCl or 0.15 M Na-acetate and 4 mM NaCl in the presence or absence of listed ionophores (1 μM each). After incubation for 5 min, ATP uptake was started as described. 100 % control corresponded to 16.0 ± 1.3 nmole/mg protein/2 min. In some experiments, proteoliposomes were prepared in the 20 mM MES, pH 5.5, 0.15 M K-acetate and 4 mM KCl. Then, proteoliposomes were added to the assay.
solution, pH 7.0 or 7.5, 0.15 M K-acetate and 4 mM KCl. ATP uptake at 2 min was measured.